|
|
| | CARBACYCLIN Basic information |
| Product Name: | CARBACYCLIN | | Synonyms: | 6,9ALPHA-METHYLENE-11ALPHA,15S-DIHYDROXY-PROSTA-5E,13E-DIEN-1-OIC ACID;6A-CARBA-PROSTAGLANDIN I2;carboprostacyclin;6,9-Methanoprostaglandin I2;6a-Carba-prostaglandinI2, CarbocyclicPGI2;(5E)-6a-Carbaprostaglandin 12;5-[(1β,3E,5β,6R)-6β-[(1E,3S)-3-Hydroxy-1-octenyl]-7α-hydroxybicyclo[3.3.0]octane-3-ylidene]pentanoic acid;5-[(2E,3aS,5R,6aβ)-Octahydro-5α-hydroxy-4β-[(1E,3S)-3-hydroxy-1-octenyl]pentalen-2-ylidene]pentanoic acid | | CAS: | 69552-46-1 | | MF: | C21H34O4 | | MW: | 350.49 | | EINECS: | 636-209-4 | | Product Categories: | | | Mol File: | 69552-46-1.mol |  |
| | CARBACYCLIN Chemical Properties |
| Melting point | 65-67℃ | | Boiling point | 514.8±50.0 °C(Predicted) | | density | 1.177±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | Soluble at 20mg/ml in ethanol. | | form | Solid | | pka | 4.77±0.10(Predicted) |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 22-36 | | WGK Germany | 3 |
| | CARBACYCLIN Usage And Synthesis |
| Uses | Carbacyclin acts as a converter of human white to bright adipocytes. Also used in the treatment of high-risk acute lymphoblastic leukemia potentiating the activity of anti-cancer therapeutics. | | Uses | Carbacyclin is a stable analog of PGI2. When infused in rabbits or dogs, it inhibits ex vivo platelet aggregation, but the effect persists only 10 minutes after termination of the infusion. Carbacyclin is a stable analog of PGI2. Carbacyclin inhibits platelet aggregation with 10% of the molar potency exhibited by PGI2. The ED50 of Carbacyclin for the in vitro inhibition of ADP-induced platelet aggregation in human PRP is 47 nM. It was also shown to effect terminal differentiation of preadipose into adipose cells and enhance the expression of angiotensinogen and adipose fatty acid binding protein with an EC50 of about 0.5 μM. | | Definition | ChEBI: Carbaprostacyclin is a prostanoid. |
| | CARBACYCLIN Preparation Products And Raw materials |
|